Matisse Capital Biohaven Pharmaceutical Holding CO Ltd. Call Options Transaction History
Matisse Capital
- $205 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BHVN
# of Institutions
11Shares Held
792KCall Options Held
0Put Options Held
0-
Knoll Capital Management, LLC Miami, FL710KShares$30.4 Million17.51% of portfolio
-
Eaton Vance Management Boston, MA35.9KShares$1.54 Million0.01% of portfolio
-
S. Muoio & Co. LLC New York, NY19KShares$812,1543.79% of portfolio
-
Agf Investments LLC Boston, MA11.6KShares$494,6520.16% of portfolio
-
Birchview Capital, LP Burlington, VT7.37KShares$315,1480.34% of portfolio
About Biohaven Pharmaceutical Holding Co Ltd.
- Ticker BHVN
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,645,000
- Market Cap $3.07B
- Description
- Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...